Swen, J. J. Et Al. 2023. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. The Lancet , vol.401, no.10374 , 347-356.

Swen, J. J., van der Wouden, C. H., Manson, L. E., Abdullah-Koolmees, H., Blagec, K., Blagus, T., ... Böhringer, S.(2023). A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. The Lancet , vol.401, no.10374, 347-356.

Swen, Jesse Et Al. "A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study," The Lancet , vol.401, no.10374, 347-356, 2023

Swen, Jesse J. Et Al. "A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study." The Lancet , vol.401, no.10374, pp.347-356, 2023

Swen, J. J. Et Al. (2023) . "A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study." The Lancet , vol.401, no.10374, pp.347-356.

@article{article, author={Jesse J Swen Et Al. }, title={A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study}, journal={The Lancet}, year=2023, pages={347-356} }